图片
荣富国际logo
会员登录
登录账号:
登录密码:
验 证 码:
您好,您已登录
您有条新到站内短信
会员中心 退出登录
图片
点评分类
点评搜索
点评详情
发布于:2018-12-6 22:28:40  访问:46 次 回复:0 篇
版主管理 | 推荐 | 删除 | 删除并扣分
Traits, like K-Ras mutation status. However, patients previously treated by bevacizumab
Median TTP was six.three months in AA sufferers (7 individuals, 6 events) vs two.9 months in AG patients (35 sufferers, 31 events) vs two.six months in GG patients (12 sufferers, 12 events); Log Rank test: p = 0.037. Comparison of AA+AG sufferers (median TTP two.9 months) vs GG patients gave a p worth at 0.016.stepwise evaluation performed on the complete population, PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/26437915 such as each gene polymorphisms viewed as as ternary variables in addition to bevacizumab pre-treatment (yes/no), revealed that CCND1 A870G (p = 0.044) and FCGR3A F158V (p = 0.006) polymorphisms have been considerable independent survival Gepotidacin cost predictors (p = 0.014 for bevacizumab pre-treatment). Lastly, this latter result was confirmed within a multivariate stepwise evaluation carried out in the sub-group of sufferers with wt KRas tumors (p values had been 0.021, 0.036 and 0.058 for CCND1, FCGR3A and bevacizumab pre-treatment, respectively).Discussion Cetuximab has shown efficacy in sufferers with metastatic colorectal cancer in a number of phase II trials top, in 2004, to FDA approval for the therapy of irinotecanrefractory metastatic colorectal cancer.Traits, like K-Ras mutation status. However, sufferers previously treated by bevacizumab had a substantially shorter survival (median 4.9 months, PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28607003 13 individuals, 11 cancer-related deaths) than people who did not acquire bevacizumab (median 9.8 months, 44 sufferers, 33 cancer-related deaths, p = 0.018). Univariate analyses revealed a important influence of FCGR3A F158V polymorphism on survival (FF vs FV vs VV, p < 0.001), with the 6 VV patients having a markedly shorter survival (Figure 5). The influence of CCDN1 A870G polymorphism was at the limit of significance (AA vs AG vs GG, p = 0.050, Figure 6), with GG patients exhibiting the poorest survival. Other gene polymorphisms had no influence on specific survival. Univariate analyses conducted in the sub-group of patients with KRas wt tumors confirmed the impact of FCGR3A F158V polymorphism on survival (median 9.9, 9.0 and 2.9 months in FF, FV and VV patients, respectively, p = 0.003) and reinforced the significance of CCND1 A870G polymorphism (medians 9.9, 9.9 and 2.9 months in AA, AG and GG patients, respectively, p = 0.024). A multivariateDahan et al. BMC Cancer 2011, 11:496 http://www.biomedcentral.com/1471-2407/11/Page 6 of94.3Prog+Stab CR+PRNumber of patients91.757.142.9AA5.7AG8.3GGA870G CCND1 polymorphismFigure 2 Relationship between best clinical response and CCND1 A870G gene polymorphism on the whole population. P value of chisquare test was 0.016 for AA vs AG vs GG, 0.004 for AA vs AG+GG and 0.73 for AA+AG vs GG. Response rate was 6.4 in AG+GG patients and 11.9 in AA+AG patients.1.CC (N=43) CA+AA (N=11+1)0.Probability0.0.0.0.TTP (months)Figure 3 TTP probability according to EGFR -191C > A gene polymorphism on the complete population. Median TTP was 2.9 months in CC patients (43 individuals, 38 events) vs 2.six months in CA+AA patients (12 individuals, 12 events); Log Rank test: p = 0.050.Dahan et al.
共0篇回复 每页10篇 页次:1/1
共0篇回复 每页10篇 页次:1/1
我要回复
回复内容
验 证 码
看不清?更换一张
匿名发表 
图片
脚注信息
版权所有 Copyright(C)2009-2020  荣富国际茶叶贸易有限公司